Ticker Scorecard - RLMD Basics Company: Relmada Therapeutics, Inc. IPO Date: June 16, 2014 Sector: Healthcare Industry: Biotech Market Cap: $8.9M Activated in VL: True Average Daily Range Avg Daily Range: $0.58 | 3.49% Avg Daily Range (30 D): $0.02 | 5.09% Avg Daily Range (90 D): $0.05 | 4.61% Institutional Daily Volume Avg Daily Volume: .26M Avg Daily Volume (30 D): 1.16M Avg Daily Volume (90 D): .94M Trade Size Avg Trade Size (Sh.): 110 Avg Trade Size (Sh.) (30 D): 567 Avg Trade Size (Sh.) (90 D): 432 Institutional Trades Total Inst.Trades: 365 Avg Inst. Trade: $2.13M Avg Inst. Trade (30 D): $.6M Avg Inst. Trade (90 D): $.6M Avg Inst. Trade Volume: .09M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $2.27M Avg Closing Trade (30 D): $M Avg Closing Trade (90 D): $M Avg Closing Volume: 102.03K     News Dec 9, 2024 @ 12:30 PM Relmada Therapeutics to Discontinue the Reliance I... Source: Globe Newswire Feb 1, 2024 @ 1:42 PM Relmada Therapeutics And 2 Other Penny Stocks Insi... Source: Avi Kapoor Jan 4, 2024 @ 6:37 PM Why Mobileye Global Shares Are Trading Lower By Ov... Source: Avi Kapoor Sep 21, 2023 @ 5:25 PM Relmada (RLMD) Up on Positive Data for Anti-Depres... Source: Zacks Equity Research Aug 7, 2023 @ 4:06 PM FDA's Rejection of Sage/Biogen's Zuranolone Boosts... Source: Vandana Singh Financials   TTM Q2 2024 Q1 2024 Basic EPS $-.72 $-.59 $-.72 Diluted EPS $-.72 $-.59 $-.72 Revenue $ M $ M $ M Gross Profit $ $ $ Net Income / Loss $ -21.73M $ -17.77M $ -21.83M Operating Income / Loss $ -23.01M $ -18.82M $ -22.99M Cost of Revenue $ $ $ Net Cash Flow $ -.6M $ .75M $ -2.76M PE Ratio     Splits Sep 30, 2019:   4:1 Aug 12, 2015:   5:1